Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.
Cellectar Biosciences develops proprietary oncology drugs built around its Phospholipid Drug Conjugate™ (PDC) delivery platform. News about CLRB commonly centers on targeted radiotherapeutic programs, including iopofosine I 131 for Waldenström macroglobulinemia and CLR 121125, also called CLR 125, an iodine-125 Auger-emitting program for solid tumors such as triple negative breast, lung and colorectal cancers.
Company updates also cover clinical data from the CLOVER WaM study, oncology conference presentations, European and U.S. regulatory interactions, intellectual property protection, securities financings, and periodic financial results with corporate updates. The recurring disclosures reflect a late-stage clinical biopharmaceutical company funding and advancing cancer-cell-targeting treatments through internal development and research collaborations.
Cellectar Biosciences (NASDAQ: CLRB), a clinical biopharmaceutical company, will host a key opinion leader event on July 24, 2024, at 8:00 a.m. EDT. This event will cover the latest data from the CLOVER WaM pivotal trial of iopofosine I 131 for Waldenstrom’s macroglobulinemia. The company aims to offer a comprehensive review of the trial's results, current treatment landscape, unmet patient needs, and potential improvements in patient outcomes. The event will feature insights from both company leaders and key study investigators. A replay of the conference call will be available on the company's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB) has formed a strategic partnership with City of Hope Cancer Center to evaluate the efficacy of its lead drug, iopofosine I 131, in treating mycosis fungoides (MF), a rare form of non-Hodgkin's lymphoma (NHL). This collaboration aims to initiate trials with around 10 patients by late 2024 or early 2025. Iopofosine I 131, the first systemic targeted radiotherapeutic for cutaneous T-cell lymphomas (CTCL), may provide advantages over conventional treatments by targeting tumor cells beyond the skin. Cellectar is set to submit a New Drug Application (NDA) to the FDA in late 2024 based on its CLOVER WaM pivotal study results in Waldenstrom's macroglobulinemia (WM).
Cellectar Biosciences (NASDAQ: CLRB) reported its Q1 2024 financial results and shared a corporate update. Key highlights include positive topline data from the CLOVER WaM pivotal study for iopofosine I 131 in Waldenstrom’s macroglobulinemia, which met its primary endpoint with a major response rate of 61% and an overall response rate of 75.6%. Further data for all evaluable patients will be announced in June 2024. The company also reported a complete remission rate of 64% in a Phase I study of iopofosine in recurrent head and neck cancer. Financially, the company had $40 million in cash as of March 31, 2024, with a net loss of $21.6 million for the quarter. R&D expenses increased to $7.4 million, while G&A expenses rose to $4.6 million, contributing to the loss.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day in New York City on May 13, 2024. Jarrod Longcor, the company's COO, will provide an overview of Cellectar in a fireside chat.
Cellectar Biosciences, Inc. (NASDAQ: CLRB) will announce its first-quarter financial results on May 14, 2024. The company focuses on developing cancer treatments and will host a conference call to discuss the results and provide an overview at 8:30 am Eastern Time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.